SCHEDULE: Vanguard Group Reports 0% Stake in Vaxcyte Inc

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vaxcyte Inc. following an internal corporate realignment.

Summary

• The Vanguard Group filed Amendment No. 3 to its Schedule 13G for Vaxcyte Inc.
• As of March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Vaxcyte Inc.'s Common Stock.
• This change stems from an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following this realignment, certain Vanguard subsidiaries or business divisions now report beneficial ownership separately, on a disaggregated basis, from The Vanguard Group, Inc.
• Consequently, The Vanguard Group, Inc. no longer holds, or is deemed to hold, beneficial ownership over securities now reported by these separate entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Vaxcyte Inc. as it primarily reflects an internal organizational change at The Vanguard Group rather than a direct investment decision regarding Vaxcyte's prospects.

Positives

• The internal realignment by The Vanguard Group aims to streamline reporting, potentially enhancing transparency for specific investment strategies within its organizational structure.

Negatives

• The Vanguard Group's reported 0% beneficial ownership means it no longer holds a significant stake in Vaxcyte Inc. under its primary reporting entity, which could be interpreted as a reduction in direct institutional interest from this specific entity, although the underlying investment may still exist across its subsidiaries.

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that such internal realignments and subsequent disaggregated reporting by large institutional investors like The Vanguard Group are not uncommon. They typically reflect internal operational or compliance adjustments rather than a direct change in investment thesis regarding the underlying company, Vaxcyte Inc. However, it does mean that the aggregate beneficial ownership previously reported under The Vanguard Group will now be spread across multiple reporting entities, potentially making it less straightforward to track the total Vanguard-affiliated holdings in Vaxcyte Inc. from a single filing.

Stakeholder Impact

• Shareholders: Existing shareholders of Vaxcyte Inc. might observe a change in the reported institutional ownership structure, as Vanguard's holdings are now disaggregated. This could lead to a perception of reduced direct institutional interest, though the underlying investment might still exist across Vanguard's subsidiaries.
• Investment Professionals: Analysts tracking institutional ownership will need to account for the disaggregated reporting from Vanguard's various entities to get a complete picture of Vanguard's overall exposure to Vaxcyte Inc.

Key Dates

Recommendation

The filing primarily details an internal organizational change at The Vanguard Group, resulting in a technical adjustment to their reported beneficial ownership in Vaxcyte Inc. It does not provide new information about Vaxcyte's operational performance, financial health, or strategic direction. Therefore, a seasoned investor would likely maintain their current position, awaiting more substantive news directly related to Vaxcyte's business fundamentals.

Keywords

Vaxcyte Inc, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing, internal realignment, investment adviser